- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
7 New Drugs Approved for Primary Care: Q2 2022
Another quarter has come and gone, which means Patient Care Online has compiled another list of new drugs approved by the US Food and Drug Administration (FDA) for conditions that are often seen in primary care. Scroll through the slides below to find details on the first and only specific interleukin-23 inhibitor to be approved for the treatment of Crohn disease in adults, the first drug indicated for the treatment for eosinophilic esophagitis, and 5 more.
Missed last quarter's drug roundup? Check out 7 New Drugs Approved for Primary Care: Q1 2022
Roche, Alnylam Advance Zilebesiran Into Phase 3 CV Outcomes Trial for Resistant Hypertension
September 9th 2025Zilebesiran’s twice-yearly dosing and sustained BP reductions could offer a new therapeutic approach for adults with resistant hypertension and high CV risk who are uncontrolled on current SOC regimens.
